Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% Debt-to-Equity is 0.01 as of Dec. 2025, which is at its 10-year median of 0.01. The stock has 4 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 99.45% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Genetic Signatures's Debt-to-Equity or its related term are showing as below:
ASX:GSS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.01
During the past 11 years, the highest Debt-to-Equity Ratio of Genetic Signatures was 0.02. The lowest was 0.00. And the median was 0.01.
ASX:GSS's Debt-to-Equity is ranked better than 99.45% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ASX:GSS: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Genetic Signatures Debt-to-Equity Related Terms
Genetic Signatures Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Debt-to-Equity of 0.01 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genetic Signatures and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, Genetic Signatures ranks #1 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Genetic Signatures' Debt-to-Equity too high?
Genetic Signatures' current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Genetic Signatures' value of 0.01 is 97% below this industry median. Based on the distribution chart, Genetic Signatures ranks #1 out of 183 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #1 out of 183 companies for Debt-to-Equity. This places Genetic Signatures in the top 1% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.33. Genetic Signatures' value of 0.01 is 97% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.33, Genetic Signatures has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Debt-to-Equity of 0.01 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 97% below the Medical Diagnostics & Research industry median of 0.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Debt-to-Equity is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
